Gemini Therapeutics (GMTX) Issues Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Stifel Downgrades Gemini Therapeutics (GMTX) to Hold, Slashes Price Target to $2, Cites Lower Probability of Success for GEM103 and Higher Overall Risks
February 28, 2022 9:46 AM ESTStifel analyst Paul Matteis downgraded Gemini Therapeutics Inc. (NASDAQ: GMTX) from Buy to Hold with a price target of $2.00 (from $11.00), following the company's most recent corporate update.
The analyst quotes: "We are downgrading GMTX to Hold. Plans announced this morning to pursue strategic alternatives and lay off 80%... More
